"Competition Newsletter（January 2026）" has been published.

Contents
１．The intersection between competition law and intellectual property law in the pharmaceutical industry: Text of a decision imposing a fine on Teva (European Commission)
1.1．Introduction
1.2．Reverse payment settlements
1.3．Overview of the European Commission’s decision dated October 31, 2024 (AT.40588 - Teva Copaxone )
1.4．Does the abuse of divisional application give rise to concerns under Japan’s Act on Prohibition of Private Monopolization and Maintenance of Fair Trade?
1.5．Conclusion
２．Recent Publications
３．News (Achievements)